Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/51753
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKanhere, H.en
dc.contributor.authorLeopardi, L.en
dc.contributor.authorFischer, L.en
dc.contributor.authorKitchener, M.en
dc.contributor.authorMaddern, G.en
dc.date.issued2008en
dc.identifier.citationAustralian and New Zealand Journal of Surgery, 2008; 78(5):371-376en
dc.identifier.issn1445-1433en
dc.identifier.issn1445-2197en
dc.identifier.urihttp://hdl.handle.net/2440/51753-
dc.descriptionJournal compilation © 2008 Royal Australasian College of Surgeonsen
dc.description.abstractBackground: Hepatocellular carcinoma (HCC) is one of the most common solid organ tumours, with approximately 500 000 new cases being reported each year. It has a very high prevalence in Asia, and almost two-thirds of all cases occur in this region. The incidence of this tumour in Australia has nearly doubled in the past decade. Surgical resection is the mainstay of treatment, but only 10–30% of HCC are amenable to surgical resection at the time of diagnosis. The prognosis for patients with unresectable HCC remains dismal. Internal radiotherapy with radiolabelled lipiodol has been used with some success in treatment of HCC. Several studies have validated its usefulness in an adjuvant setting, but it also appears to have a role in treating unresectable tumours. Methods: Twenty-two patients with proven HCC, not amenable to or having failed surgical treatment, were evaluated for radiolabelled lipiodol treatment. Of these, 10 patients were excluded after initial evaluation and 12 patients underwent treatment. Patients were followed up every 3 months with physical examination, computed tomography scan and α-fetoprotein levels. Overall survival, change in tumour size and α-fetoprotein levels were used to evaluate the efficacy of treatment. Results: The median overall survival in patients undergoing lipiodol therapy was 15 months. Tumour size was stabilized in most patients and very few side-effects of the treatment were observed. Conclusion: This study has shown that radiolabelled lipiodol is an effective method for the treatment of unresectable locally advanced HCC.en
dc.description.statementofresponsibilityHarsh A. Kanhere, Lisa N. Leopardi, Louise Fischer, Michael I. Kitchener and Guy J. Maddernen
dc.language.isoenen
dc.publisherBlackwell Science Asiaen
dc.subjecthepatocellular carcinoma; lipiodol; palliative treatmenten
dc.titleTreatment of unresectable hepatocellular carcinoma with radiolabelled lipiodolen
dc.typeJournal articleen
dc.identifier.doi10.1111/j.1445-2197.2008.04480.xen
pubs.publication-statusPublisheden
dc.identifier.orcidMaddern, G. [0000-0003-2064-181X]en
Appears in Collections:Surgery publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.